Cargando…

Macrophage-Mediated Antibody Dependent Effector Function in Aggressive B-Cell Lymphoma Treatment is Enhanced by Ibrutinib via Inhibition of JAK2

Targeted inhibition of Bruton’s Tyrosine Kinase (BTK) with ibrutinib and other agents has become important treatment options in chronic lymphocytic leukemia, Waldenström’s Macroglobulinemia, Mantle cell lymphoma, and non-GCB DLBCL. Clinical trials combining small molecule inhibitors with monoclonal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barbarino, Verena, Henschke, Sinika, Blakemore, Stuart James, Izquierdo, Elena, Michalik, Michael, Nickel, Nadine, Möllenkotte, Indra, Vorholt, Daniela, Müller, Linda, Brinker, Reinhild, Fedorchenko, Oleg, Mikhael, Nelly, Seeger-Nukpezah, Tamina, Hallek, Michael, Pallasch, Christian P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465917/ https://www.ncbi.nlm.nih.gov/pubmed/32824276 http://dx.doi.org/10.3390/cancers12082303

Ejemplares similares

P1249: INHIBITION OF THE PENTOSE-PHOSPHATE-PATHWAY (PPP) MEDIATES MACROPHAGE REPROGRAMMING FROM SUPPORTIVE BYSTANDER FUNCTION TOWARDS ANTIBODY-DEPENDENT LYMPHOMA CELL CLEARANCE AND LYMPHOMA SUPPRESSION
por: Beielstein, A., et al.
Publicado: (2022)

The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia
por: Rusyn, Lisa, et al.
Publicado: (2022)

Meta-Analysis Reveals Significant Sex Differences in Chronic Lymphocytic Leukemia Progression in the Eµ-TCL1 Transgenic Mouse Model
por: Koch, Maximilian, et al.
Publicado: (2020)

Evaluation of body-surface-area adjusted dosing of high-dose methotrexate by population pharmacokinetics in a large cohort of cancer patients
por: Arshad, Usman, et al.
Publicado: (2021)

Estrogen receptor α (ERα) indirectly induces transcription of human renal organic anion transporter 1 (OAT1)
por: Euteneuer, Anna M., et al.
Publicado: (2019)

COVID‐19 complicated by parainfluenza co‐infection in a patient with chronic lymphocytic leukemia
por: Langerbeins, Petra, et al.
Publicado: (2020)

Invasive Aspergillosis in Patients Treated With Ibrutinib
por: Fürstenau, Moritz, et al.
Publicado: (2020)

The Centrosomal Kinase Plk1 Localizes to the Transition Zone of Primary Cilia and Induces Phosphorylation of Nephrocystin-1
por: Seeger-Nukpezah, Tamina, et al.
Publicado: (2012)

Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment
por: Guo, Ailin, et al.
Publicado: (2017)

Inhibiting Heat Shock Protein 90 (HSP90) Limits the Formation of Liver Cysts Induced by Conditional Deletion of Pkd1 in Mice
por: Smithline, Zachary B., et al.
Publicado: (2014)

A RASSF1A-HIF1α loop drives Warburg effect in cancer and pulmonary hypertension
por: Dabral, Swati, et al.
Publicado: (2019)

Inhibition of effector B cells by ibrutinib in systemic sclerosis
por: Einhaus, Jakob, et al.
Publicado: (2020)

Treatment of rheumatoid arthritis with baricitinib or upadacitinib is associated with reduced scaffold protein NEDD9 levels in CD4+ T cells
por: Golumba‐Nagy, Viktoria, et al.
Publicado: (2023)

Functional impact and molecular binding modes of drugs that target the PI3K isoform p110δ
por: Hassenrück, Floyd, et al.
Publicado: (2023)

Ibrutinib-induced cardiomyopathy
por: Kyi, Htay Htay, et al.
Publicado: (2019)

Extrahepatic metabolism of ibrutinib
por: Rood, Johannes J. M., et al.
Publicado: (2020)

Electrocardiographic Changes Associated With Ibrutinib Exposure
por: Fradley, Michael G., et al.
Publicado: (2020)

Ibrutinib: Rebound effect in the form of respiratory deterioration following the discontinuation of ibrutinib: case report
Publicado: (2021)

A High-Throughput Clinical Laboratory Methodology for the Therapeutic Monitoring of Ibrutinib and Dihydrodiol Ibrutinib
por: Karvaly, Gellért Balázs, et al.
Publicado: (2022)

Ibrutinib for B cell malignancies
por: Novero, Aileen, et al.
Publicado: (2014)

Ibrutinib-Induced Skin Rash
por: Kirar, Sudhir, et al.
Publicado: (2021)

Ibrutinib: Pneumonitis: case report
Publicado: (2021)

Arrhythmia Patterns in Patients on Ibrutinib
por: Fazal, Muhammad, et al.
Publicado: (2022)

Photoaging Mobile Apps: A Novel Opportunity for Smoking Cessation?
por: Brinker, Titus J, et al.
Publicado: (2015)

Profound Sinoatrial Arrest Associated with Ibrutinib
por: Mathur, Kanupriya, et al.
Publicado: (2017)

Ibrutinib‐induced severe liver injury
por: Nandikolla, Amara G., et al.
Publicado: (2017)

Ibrutinib dose modifications in the management of CLL
por: Hardy-Abeloos, Camille, et al.
Publicado: (2020)

Cystoid macular edema secondary to ibrutinib
por: Ben-Avi, Ravid, et al.
Publicado: (2022)

Death from diltiazem–ibrutinib interaction
por: Falconer, Nazanin, et al.
Publicado: (2021)

Functional Changes in Acute Eosinophilic Myocarditis Due to Chemotherapy With Ibrutinib
por: Isaza, Nicolas, et al.
Publicado: (2019)

Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis
por: O'Brien, Susan M., et al.
Publicado: (2019)

The Development of Multiple Periprosthetic Joint Infections in Conjunction With Ibrutinib Therapy
por: Muttana, Swathi, et al.
Publicado: (2021)

Ibrutinib response in a patient with refractory mixed essential cryoglobulinemia
por: Jamali, Haya, et al.
Publicado: (2023)

High incidence of atrial fibrillation in patients treated with ibrutinib
por: Baptiste, Florian, et al.
Publicado: (2019)

Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
por: von Tresckow, Julia, et al.
Publicado: (2022)

Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk
por: Stühlinger, Markus C., et al.
Publicado: (2019)

Ibrutinib and novel BTK inhibitors in clinical development
por: Akinleye, Akintunde, et al.
Publicado: (2013)

Ibrutinib for rituximab-refractory Waldenström macro-globulinemia
por: Gavriatopoulou, Maria, et al.
Publicado: (2017)

Ibrutinib-associated pityriasis rosea–like rash
por: Bitar, Carole, et al.
Publicado: (2017)

Evaluating ibrutinib in the treatment of symptomatic Waldenstrom’s macroglobulinemia
por: Papanota, Aristea-Maria, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_b38g0pbnlpn8mk5u3n9aucjn35